These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30642613)

  • 1. Pharmacokinetics and Safety of Enzalutamide in Healthy Chinese Male Volunteers.
    Liu YM; Wu P; Fukushi R; Yamada S; Chen Q
    Clin Ther; 2019 Feb; 41(2):261-268. PubMed ID: 30642613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
    Ma H; Xu W; Ni J; Zhao N; Tang S; Li S; Cai T; Xiu J; Kang X; Gao S; Zhang L; Zhou T
    Prostate; 2022 Feb; 82(2):276-285. PubMed ID: 34807458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.
    van Nuland M; Bergman AM; Rosing H; de Vries N; Huitema ADR; Beijnen JH
    Pharmacotherapy; 2019 Dec; 39(12):1137-1145. PubMed ID: 31596947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
    Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
    J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetic Studies of Enzalutamide.
    Gibbons JA; Ouatas T; Krauwinkel W; Ohtsu Y; van der Walt JS; Beddo V; de Vries M; Mordenti J
    Clin Pharmacokinet; 2015 Oct; 54(10):1043-55. PubMed ID: 25917876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.
    Akaza H; Uemura H; Tsukamoto T; Ozono S; Ogawa O; Sakai H; Oya M; Namiki M; Fukasawa S; Yamaguchi A; Uemura H; Ohashi Y; Maeda H; Saito A; Takeda K; Naito S
    Int J Clin Oncol; 2016 Aug; 21(4):773-782. PubMed ID: 26793974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer.
    Cordes LM; Schmidt KT; Peer CJ; Chau CH; Redmond E; Francis D; Karzai F; Madan RA; Figg WD
    Oncologist; 2021 Sep; 26(9):729-e1493. PubMed ID: 34333820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Drug Interaction Studies with Enzalutamide.
    Gibbons JA; de Vries M; Krauwinkel W; Ohtsu Y; Noukens J; van der Walt JS; Mol R; Mordenti J; Ouatas T
    Clin Pharmacokinet; 2015 Oct; 54(10):1057-69. PubMed ID: 25929560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients.
    Kim CS; Theeuwes A; Kwon DD; Choi YD; Chung BH; Lee HM; Lee KH; Lee SE
    Investig Clin Urol; 2016 May; 57(3):174-83. PubMed ID: 27195316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
    Graff JN; Baciarello G; Armstrong AJ; Higano CS; Iversen P; Flaig TW; Forer D; Parli T; Phung D; Tombal B; Beer TM; Sternberg CN
    Ann Oncol; 2016 Feb; 27(2):286-94. PubMed ID: 26578735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
    Joulia ML; Carton E; Jouinot A; Allard M; Huillard O; Khoudour N; Peyromaure M; Zerbib M; Schoemann AT; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Clin Genitourin Cancer; 2020 Apr; 18(2):155-160. PubMed ID: 31630979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic properties and safety profile of histamine dihydrochloride injection in Chinese healthy volunteers: a phase I, single-center, open-label, randomized study.
    Li J; Huang X; Wang Q; Jing S; Jiang H; Wei Z; Zang Y; Liu Y; Zhao L; Fang Y; Feng W
    Clin Ther; 2015 Oct; 37(10):2352-64. PubMed ID: 26276501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
    Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G
    Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions.
    Joshi S; Gudi G; Menon VCA; Tandon M; Joshi V; Suryawanshi S; Barkate H; Sawant N; Katare S; Siddique W
    Clin Pharmacokinet; 2020 Mar; 59(3):349-357. PubMed ID: 31583610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers.
    Zuo CZ; Gong Y; Hou XY; Zhang YF; Peng WX; Zhu RH; Zhong DF; Chen XY
    Clin Ther; 2018 Aug; 40(8):1347-1356. PubMed ID: 30017171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
    Li H; Butler K; Yang L; Yang Z; Teng R
    Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
    Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
    Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
    Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z
    Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
    Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
    Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
    Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.